NCT05356741Phase 1, phase 2Recruiting

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Study sponsor: Vir Biotechnology, Inc. · VIR

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-04Estimated
Enrollment · participants645Estimated
Source updated2026-11-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.